Hood River Capital Management LLC Buys Shares of 401,442 Vaxcyte, Inc. (NASDAQ:PCVX)

Hood River Capital Management LLC acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 401,442 shares of the company's stock, valued at approximately $32,862,000. Hood River Capital Management LLC owned approximately 0.32% of Vaxcyte at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of PCVX. Capital Research Global Investors raised its holdings in Vaxcyte by 26.8% in the fourth quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock valued at $508,393,000 after buying an additional 1,312,302 shares during the period. Norges Bank acquired a new stake in shares of Vaxcyte in the fourth quarter worth $90,069,000. Vanguard Group Inc. lifted its holdings in shares of Vaxcyte by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock valued at $979,184,000 after acquiring an additional 521,204 shares in the last quarter. Franklin Resources Inc. boosted its position in Vaxcyte by 13.2% during the 3rd quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company's stock worth $315,162,000 after purchasing an additional 324,560 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Vaxcyte during the 4th quarter worth $21,669,000. Institutional investors and hedge funds own 96.78% of the company's stock.

Vaxcyte Stock Performance

Shares of PCVX stock opened at $31.26 on Wednesday. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06. The stock's 50 day simple moving average is $58.56 and its 200 day simple moving average is $81.72. The company has a market capitalization of $4.03 billion, a price-to-earnings ratio of -6.80 and a beta of 1.26.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.16) by $0.14. On average, analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analysts Set New Price Targets

PCVX has been the subject of a number of recent research reports. Bank of America lowered their target price on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Guggenheim restated a "buy" rating and issued a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, March 12th. Cantor Fitzgerald started coverage on Vaxcyte in a report on Tuesday. They set an "overweight" rating on the stock. The Goldman Sachs Group lowered their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Needham & Company LLC restated a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $136.50.

Insider Activity at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at approximately $11,351,794.37. This represents a 4.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 24,000 shares of company stock valued at $1,946,720 over the last ninety days. 3.10% of the stock is owned by insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.